Matthew D. Hellmann

Matthew D. Hellmann, MD, is an Associate Attending Physician and Member of the Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center, and one of the most influential investigators defining the role of immunotherapy in non-small cell lung cancer. His research has centered on understanding who benefits from immune checkpoint inhibition and why, with a particular focus on tumor mutational burden (TMB) as a predictive biomarker and on the rational design of combination immunotherapy regimens. He led pivotal analyses establishing TMB as a biomarker for response to nivolumab plus ipilimumab in the CheckMate 227 trial, positioning dual checkpoint blockade as a first-line option in TMB-high NSCLC. Hellmann's translational research program at MSK integrates tumor genomics, immune profiling, and clinical outcome data to delineate the molecular and immunological determinants of response and resistance to immune checkpoint inhibitors. His work on the PD-L1/TMB co-biomarker model and subsequent analyses refining its predictive value have influenced both regulatory decisions and clinical practice guidelines. Beyond TMB, he has studied co-occurring genomic alterations—including KRAS, STK11, and KEAP1 mutations—that modulate immune activity in NSCLC, advancing a more nuanced understanding of immunotherapy responsiveness. Hellmann is a prolific author and frequent presenter at international oncology congresses, with contributions appearing in the New England Journal of Medicine, Nature, and Nature Medicine, among others. He is an active mentor and has helped train multiple clinical investigators in the field of cancer immunotherapy. His work exemplifies how deep molecular characterization can translate into refined patient selection for immunotherapy, maximizing benefit while guiding the development of next-generation approaches for immunotherapy-refractory disease.